Safety Shot, Inc. (NASDAQ:SHOT) (“SHOT” or the “Company”), makers of the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity is providing a litigation update to the market regarding its newly filed lawsuit against Capybara research.
On December 4th 2023, we filed a federal lawsuit in the United States District Court for the Southern District of New York against Capybara Research, a firm recently created and that enjoyed anonymity through various social media postings without any trail as to ownership while antagonizing our retail investment community by posting lewd and unprofessional graphics, intended to further embarrass the Company.
Today, after weeks of investigatory work by our counsel, as well as the cooperation of third parties, we wish to announce that our attorneys have been successful in identifying the person responsible for the malicious article and is now taking all steps necessary to add to the lawsuit the name of the individual, as well as his address, and to serve that individual.
Today we also announced that we also adding to our federal lawsuit the social media news outlet Benzinga for republishing, and continuing to republish the Capybara research and other false reports that continue to harm our retail investment community. We have also asked our new counsel to review all prior fundings the Company has done in order to determine whether they were done appropriately or if our rights have been violated.
“We are committed to legally pursue all short and distort campaigns against the Company as well as all media outlets that irresponsibly reported the false, misleading and defaming Capybara Report,” stated Brian S John, CEO.
The Company had previously announced that it retained known dilution funder combatant Mark R. Basile, Esq, and his Securities and RICO litigation firm, The Basile Law Firm P.C. to assist the Company in investigating and prosecuting all claims in defense of the Company and its retail investors.
About The Basile Law Firm P.C.
Mr. Basile, a former law professor, has battled dilution funding for the last 8 years. In 2021, his firm secured a landmark decision against a dilution funder that has set the standard to save hundreds of public companies’ tens of millions of dollars. Since that decision, his firm has vacated several federal trial court judgments and consequently many of the dilution funders have not filed suits against public companies in the last 18 months.
His firm is also pursuing several RICO actions against known dilution funders for the collection of unlawful debt and because of his actions, the Southern District of New York recently denied a toxic dilution funders’ motion to dismiss RICO claims. The firm has also published articles and advice for companies that believe they may be victims of unlawful dilution, counterfeit shares and market manipulation by brokers, investment relation firms and short-sellers, a summary of which can be found at: https://www.thebasilelawfirm.com/blog
